Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Vaxart ( (VXRT) ).
On April 16, 2026, Vaxart, Inc. entered into a purchase agreement and related registration rights agreement with Lincoln Park Capital Fund, under which Lincoln Park committed to buy up to $25 million of Vaxart common stock over a 24‑month period, subject to specified conditions and a 4.99% ownership cap. Vaxart issued 447,067 shares as commitment consideration, and any additional sales will rely on an effective SEC registration statement and will be priced at formula-based discounts to prevailing market prices, with no warrants, rights of first refusal or participation rights attached.
The structure gives Vaxart sole discretion over the timing and size of stock sales, including potential regular and accelerated purchases, while obligating Lincoln Park to buy shares and prohibiting it from short selling or hedging the stock. The company expects to use any proceeds for working capital, capital expenditures and general corporate purposes, framing the facility as a flexible way to strengthen its balance sheet and support the advancement of its oral vaccine programs without immediately diluting shareholders through a large, one‑time equity raise.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
The score is driven primarily by improved financial performance (TTM profitability and positive cash flow) and constructive earnings-call factors (partnership validation, strong 2025 revenue, and runway extension), tempered by concerns about durability given contract-driven revenue and historical volatility. Technical signals are mixed and do not currently indicate strong near-term momentum, while valuation looks supportive but depends on earnings sustainability.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant vaccines delivered in pill form using its proprietary platform. Its pipeline targets coronavirus, norovirus and influenza prevention, as well as a therapeutic human papillomavirus vaccine, with a focus on room‑temperature stable, needle‑free products supported by broad patent filings.
Vaxart’s pill-based vaccines are designed to simplify storage, shipping and administration versus traditional injectable vaccines. The company aims to create oral versions of existing vaccines and new candidates for emerging indications, positioning itself within the competitive global vaccines market.
Average Trading Volume: 513,121
Technical Sentiment Signal: Hold
Current Market Cap: $175.5M
See more data about VXRT stock on TipRanks’ Stock Analysis page.